Jan. 13 at 9:19 PM
$RPID
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Tuesday, 13th January at 4:15 pm
Fourth quarter 2025 total revenue expected to be approximately
$11.3 million, representing growth of approximately 37% compared to the prior-year period.
Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing network.
Full year 2025 total revenue expected to be approximately
$33.6 million, representing growth of approximately 20% compared to the prior year.
LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarter and full year 2025 revenue.
For the fourth quarter of 2025, the Company expects record revenue of approximately
$11.3 million, representing growth of approximately 37% compared to the prior-year period. Fourth quarter 2025 recurring revenue is expected to be approximately
$4.6 million, representing growth of approximately 10% compared to the prior-year period. These results include the placement of a record 16 new Growth Direct systems and completion of the validation of three customer systems in the fourth quarter.
For the full year 2025, the Company expects revenue of approximately
$33.6 million, representing growth of approximately 20% compared to the prior year. Full-year 2025 recurring revenue is expected to be approximately
$17.8 million, representing growth of approximately 15% compared to the prior year. These results include the placement of 28 new Growth Direct systems and completion of the validation of 18 customer systems during 2025. Cumulatively, the Company has now placed 190 systems globally with 155 systems validated.
"We are pleased to report record results for the fourth quarter that exceeded our raised guidance issued in November," said Robert Spignesi, President and CEO. "For the full-year 2025, broad-based strength across systems, consumables and services delivered 20% revenue growth, including double-digit recurring revenue growth."
"As we enter 2026, we believe the Company is well-positioned for continued growth supported by our proven track record of consistent execution, validation of the Growth Direct platform through multi-system and follow-on customer orders, and the further advancement of our global strategic partnership with MilliporeSigma."
The Company plans to announce complete financial results for the fourth quarter and full year 2025 and host a webcast to discuss those results as well as its 2026 outlook later in the first quarter of 2026.
